Selected References:
- Auyeung-Kima DJ, et al. 2009. Developmental and peripostnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reproductive Toxicology, 28:443-455.
- Beaulieu DB, et al. 2018. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol, 16(1):99–105.
- Benlysta® Prescribing Information. 2023. Available online at https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF.
- 2013. Use of intravenous (IV) benlysta in pregnant patients with systemic lupus erythematosus (SLE). As cited in Ostensen M. 2014. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann NY Acad Sci, 1317:32-38.
- Julsgaard M, et al. 2016. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology, 151:110-119.
- Kathpalia P, et al. 2016. Detectable drug levels in infants exposed to biologics: so what? Gastroenterology, 151:25–26.
- Kao JH, et al. 2021. Pregnancy outcomes in patients treated with belimumab: report from real-world experience. Semin Arthritis Rheum, 51(5):963-968.
- Martin Bortlik, et al. 2014. Impact of anti–tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflammatory Bowel Diseases, 20(3):495–501.
- Miller RK, et al. 2014. ABSTRACT. Preliminary data from the Belimumab Pregnancy Registry: international prospective cohort study of pregnancy outcomes. OTIS/ENTIS meeting, Toronto, Canada.
- Peart E, Clowse MEB. 2014. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol, 26:118-123.
- Sandhu VK, et al. 2015. Monoclonal antibodies, systemic lupus erythematosus, and pregnancy. J Rheumatol, 42:728-730.
- Skorpen, GC. et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis, 75(5):795-810.
- Vela-Casasempere, P, et al. 2024. Considering belimumab during pregnancy: a more viable option over time. Lupus 33(7): 700-715.
